http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
Aliasghar Keramatinia,Alireza Ahadi,Mohammad Esmaeil Akbari,Maryam Mohseny,Alireza Mosavi Jarahi,Narjes Mehrvar,Neda Mansouri,S.A. Mortazavi Tabatabaei,Abolfazl Movafagh 대한암예방학회 2017 Journal of cancer prevention Vol.22 No.2
Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and clinic management. The technical monitoring of BCR-ABL1 with quantitative real time-PCR has been used in assessing patient outcome. The cytogenetic mark of CML is Philadelphia chromosome, that is formed by reciprocal chromosomal translocations between human chromosome 9 and 22, t(9:22) (q34:q11). It makes a BCR-ABL1 fusion protein with an anomaly tyrosine kinase activity that promotes the characteristic proliferation of progenitor cells in CML and acute lymphoblastic lymphoma. The targeting of BCR-ABL1 fusion kinase is the first novel paradigm of molecularly targeted curing.